Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
Carcinoma, Renal Cell
DRUG: Sorafenib (Nexavar, BAY 43-9006)
Duration of Nexavar treatment, up to 3 years
Overall Survival (OS), 1 - 1.5 years after LPLV|Health related quality of life (HRQoL), up to 3 years|Progression-free survival (PFS), up to 3 years|Tumor status, of patients will be evaluated according to the categories "Complete Response", "Partial Response", "Stable Disease", "Clinical Progression", "Radiological Progression"., up to 3 years|Incidence of Treatment-emergent Adverse Events (TEAE), up to 3 years
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.